Oral and inhaled Nadolol are two separate programmes. Smoking cessation is about the only market which will accept an oral drug, given the competition in the market place. I would expect that it will be snapped up by one of the majors with a large market in this space. In fact, I do not see how Pfizer can let it go to anyone else. They are in big trouble with their current drug, having recently settled a class action for about $300M. It is a pretty important market for them. It is also quick to market.
The inhaled programme is a little different. It has to start from scratch, with some animal trials, Phase 1 and so on. It will then have to establish a market. A very much larger investment but huge rewards. I can't see one crowding out the other.
IVX Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)